Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kaili Medical (300633), indicating a decline in stock price and mixed financial results [1][2]. - As of February 2, 2026, Kaili Medical's stock closed at 27.16 yuan, down 2.13%, with a trading volume of 37,100 hands and a total transaction amount of 102 million yuan [1]. - The company's main business involves the independent research, production, and sales of medical diagnostic and treatment equipment [2]. Group 2 - In the third quarter of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, a year-on-year increase of 4.37%, while the net profit attributable to shareholders decreased by 69.25% to 33.51 million yuan [2]. - The third quarter also saw a single-quarter main revenue of 495 million yuan, reflecting a year-on-year increase of 28.42%, but a net profit of -13.52 million yuan, which is an increase of 78.05% compared to the previous year [2]. - The company has a debt ratio of 24.22%, with an investment income of 2.08 million yuan and financial expenses of -38.30 million yuan, while maintaining a gross profit margin of 60.36% [2]. Group 3 - Over the last 90 days, five institutions have provided ratings for Kaili Medical, with four buy ratings and one hold rating [3]. - The article explains the concept of fund flow, indicating that the net flow of funds is determined by the difference between buying and selling pressures in the market [3].

Group 1: ETF Performance - As of February 2, 2026, the Medical Equipment ETF (159873) had a turnover of 5.82% with a transaction volume of 14.6087 million yuan, while the tracked index, the CSI All Share Healthcare Equipment and Services Index (H30178), fell by 1.44% [1] - The Medical Equipment ETF (159873) saw a net subscription of 11 million shares during the trading session [2] - The Biopharmaceutical ETF (159859) had a turnover of 3.87% with a transaction volume of 142 million yuan, and the corresponding index, the National Biopharmaceutical Index (399441), decreased by 2.18% [2] Group 2: Fund Flows - The Medical Equipment ETF (159873) experienced a net inflow of 4.2585 million yuan, with a total of 22.8076 million yuan net inflow over the last five trading days [2] - The Biopharmaceutical ETF (159859) achieved a new high in scale at 3.705 billion yuan and a new high in shares at 9.396 billion shares as of January 30 [3] - The Biopharmaceutical ETF (159859) has seen continuous net inflows over the past ten days, totaling 425 million yuan [3] Group 3: Sector Insights - The Medical Equipment ETF (159873) has a high content of brain-computer interface technology, accounting for over 17%, indicating strong technological attributes [3] - The overall industry landscape for medical devices is improving, with leading companies showing performance recovery in Q3, suggesting potential for future capital inflows [6] - The innovative drug sector is expected to see a recovery phase, with a focus on domestic innovation and increased global participation, indicating a positive outlook for investment opportunities [7]

Core Viewpoint - The financial performance of Kaili Medical (300633) shows mixed results, with revenue growth but significant declines in net profit, indicating potential challenges ahead for the company [2]. Group 1: Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, up 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Group 2: Market Activity - As of January 30, 2026, Kaili Medical's stock closed at 27.75 yuan, reflecting an increase of 0.65% [1]. - The turnover rate was 0.87%, with a trading volume of 37,600 hands and a transaction amount of 104 million yuan [1]. - On January 30, the net inflow of main funds was 2.97 million yuan, accounting for 2.85% of the total transaction amount [1]. - Retail investors experienced a net outflow of 2.17 million yuan, representing 2.08% of the total transaction amount [1]. - Over the past 90 days, 8 institutions have provided ratings for the stock, with 6 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 37.0 yuan [2].

Core Viewpoint - The article emphasizes the importance of systematic training and collaboration in the field of endoscopy, particularly through the "Belt and Road Friendship International Endoscopy Academy" project initiated by Kaili Medical, which aims to enhance the skills of endoscopists across multiple countries [2][4][6]. Group 1: Training and Educational Initiatives - In 2025, Kaili Medical will conduct a series of training activities in five cities: Nanchang, Beijing, Zunyi, Shanghai, and Xi'an, attracting over 50 endoscopists from 11 countries [4][6]. - The training program includes a comprehensive curriculum that covers complex procedures, emphasizing standardized teaching frameworks to ensure high-quality and consistent educational content [6][8]. - The training structure consists of theoretical lectures, observational procedures, hands-on practice, and case discussions, allowing participants to master skills and apply them effectively in clinical settings [8]. Group 2: Talent and Technical Empowerment - Kaili Medical is building a dual empowerment system combining talent and technology to facilitate the learning and replication of complex endoscopic procedures [9]. - The training emphasizes a closed-loop design of "theory-observation-practice-review," enabling participants to develop a comprehensive understanding and practical application of procedures [9][12]. - The new generation of smart endoscopy platform, iEndo, is integrated into the teaching and clinical processes, ensuring that the equipment meets the demands of high-intensity training and continuous use [13][19]. Group 3: Technological Advancements - iEndo features advanced imaging capabilities, including super-resolution imaging and adaptive lighting, which enhance the clarity and detail of images during procedures [17][19]. - The system architecture of iEndo employs a multi-core heterogeneous design, ensuring stable and high-quality imaging during complex tasks [19]. - AI is embedded in the workflow as an assistant, providing visual prompts and support without interfering with the clinician's judgment, thus enhancing the overall efficiency of the procedures [21][20]. Group 4: Long-term Collaboration and Impact - The training initiatives are not just about knowledge transfer; they aim to establish a long-term collaborative platform among international physicians, fostering shared experiences and learning across different healthcare systems [12][24]. - The approach taken by Kaili Medical reflects a shift towards a more structured and sustainable model of international medical collaboration, integrating training methods and diagnostic logic into global partnerships [22][24].

开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 证券之星消息，截至2026年1月27日收盘，开立医疗(300633)报收于28.3元，下跌1.97%，换手率 0.81%，成交量3.5万手，成交额9904.12万元。 1月27日的资金流向数据方面，主力资金净流入358.38万元，占总成交额3.62%，游资资金净流出127.24 万元，占总成交额1.28%，散户资金净流出231.13万元，占总成交额2.33%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 该股最近90天内共有8家机构给出 ...

（来源：淘金ETF） 2026年1月20日，国家疾控局联合国家发改委、财政部、国家卫生健康委等六部委正式印发《疾病预防 控制领域强基实施方案》（国疾控规财发〔2026〕3号），锚定2027、2030两大阶段目标，以"基础补短 板、设备标准化、数智化升级"为核心抓手，全面部署疾控体系强基工程；1月27日公开发布，政策红利 正式释放，万亿级公共卫生设备市场需求被激活，医疗器械板块迎来政策驱动下的设备更新与产业升级 黄金机遇期。 核心痛点亟待破解，政策精准施策 当前我国疾控体系仍面临"资源不均、设备滞后、数智薄弱"三大痛点——基层医疗机构基础诊疗设备普 及率，大量设备超期服役，中西部县域疾控设备达标率低；疾控资源80%集中在城市高端医疗机构，县 域及乡镇疾控"硬件""软件"双重薄弱；传统监测预警、流调溯源依赖人工，数智化应用未覆盖基层末 梢。与此同时，人口老龄化推升慢性病防控压力，公共卫生应急响应对设备标准化、数智化的要求持续 升级，筑牢基层疾控网底成为"健康中国"建设的关键一环。本次六部委从印发到公开发布的密集动作， 正是瞄准这些核心痛点的精准施策，既是落实中央经济工作会议"医疗卫生强基工程"的关键举措，更是 为 ...

[Table_Reportdate] 2026年01月27日 [证券分析师： Table_Authors] 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 陈伟业 cwy@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20260127 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [table_summary] ➢ 1.药品零售新政出台，赋能行业高质量发展——医药生物行业周报（2026/01/19- 2026/01/25） ➢ 2.2026年全球AI服务器出货同比有望增超28%，AI相关芯片涨价持续——电子行业周报 2026/1/19-2025/1/25 ➢ 1.商务部：将优化实施消费品以旧换新，促进家电等大宗耐用商品消费 ➢ 2.上期所调整白银、锡期货相关合约交易限额 ➢ 3.香港特别行政区行 ...

证券之星消息，截至2026年1月26日收盘，开立医疗(300633)报收于28.87元，下跌0.62%，换手率 1.48%，成交量6.42万手，成交额1.83亿元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 1月26日的资金流向数据方面，主力资金净流入143.99万元，占总成交额0.79%，游资资金净流出234.54 万元，占总成交额1.28%，散户资金净流入90.55万元，占总成交额0.49%。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry is expected to outperform the broader market index (CSI 300) by at least 10% over the next six months [1]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.39% during the week of January 19-23, 2026, ranking 27th among 31 sectors, while outperforming the CSI 300 index by 0.23 percentage points. The current PE valuation for the sector stands at 30.27 times, which is at the historical median level, with a valuation premium of 126% compared to the CSI 300 [5][16][23]. - The top-performing sub-sectors during this period were pharmaceutical commerce (4.26%), traditional Chinese medicine II (0.89%), and medical devices (0.30%) [5][14]. - A total of 330 stocks (69.62%) in the sector rose, while 137 stocks (28.90%) fell. The top five gainers included *ST Changyao (70.37%), Hualan Biological Engineering (32.21%), and Kangzhong Medical (25.47%) [5][31]. Market Performance - The pharmaceutical and biotechnology sector's performance for the year-to-date shows an increase of 6.66%, ranking 16th among 31 sectors and outperforming the CSI 300 index by 5.10 percentage points. The sub-sectors that achieved growth included medical services (13.53%), medical devices (9.50%), and pharmaceutical commerce (7.77%) [16][22]. - The PE valuations for various sub-sectors are as follows: medical devices (36.13), chemical pharmaceuticals (34.34), biological products (33.61), medical services (32.89), traditional Chinese medicine II (22.22), and pharmaceutical commerce (17.16) [23][30]. Industry News - On January 22, 2026, nine government departments, including the Ministry of Commerce and the National Health Commission, jointly issued guidelines aimed at promoting high-quality development in the pharmaceutical retail industry. The policy focuses on six key areas, emphasizing a combination of government guidance and market leadership to enhance professional and intensive development within the industry [6][33]. - The guidelines encourage the integration of pharmaceutical services, improvement of pharmacy service capabilities, and the promotion of prescription circulation and medical insurance outpatient coordination services. They also support the establishment of a commercial insurance payment system and the expansion of health management services [6][33][34]. Investment Recommendations - The report suggests a cautious approach to the pharmaceutical and biotechnology sector, highlighting the recent weak performance of previously popular stocks. It emphasizes the importance of the new guidelines in transforming the industry from a "single drug sales" model to a "health service" model [6][34]. - The report recommends focusing on leading chain pharmacies with strong financial capabilities and merger integration abilities, as well as innovative drug chains, medical devices, healthcare services, and second-class vaccines for potential investment opportunities [6][34][7].

Investment Rating - The report indicates a positive outlook for the medical equipment industry, with an expected year-on-year growth of 25% for the year 2025 [22]. Core Insights - The medical equipment industry is experiencing a slight decline in December data year-on-year, attributed to a high base effect from the previous year. However, there is a significant month-on-month increase of 38% due to accelerated budget spending at year-end [3]. - The report highlights that the current round of medical equipment upgrades is nearing its end, with expectations for a new round of equipment replacement in 2025, which is projected to be no less than the previous round [4]. - The report emphasizes the importance of government policies, including the issuance of long-term special bonds to support large-scale equipment upgrades and consumer replacement programs [15]. Summary by Relevant Sections Medical Imaging - December figures for medical imaging reached 9.8 billion yuan, a decrease of 11%, while the forecast for 2025 is 69.3 billion yuan, reflecting a growth of 37% [5]. Life Information and Support - In December, life information and support equipment generated 2.6 billion yuan, an increase of 8%, with a projected total of 16.7 billion yuan for 2025, marking a 28% growth [5]. Endoscopes - Soft endoscopes reported 1.1 billion yuan in December, down 9%, while hard endoscopes reached 1.2 billion yuan, down 7%. The 2025 projections for both are 7.8 billion yuan for soft endoscopes (+12%) and 7.8 billion yuan for hard endoscopes (+3%) [5]. Radiation Therapy - December figures for radiation therapy stood at 1.6 billion yuan, a slight increase of 1%, with a forecast of 9.6 billion yuan for 2025, indicating a growth of 32% [48]. Surgical Robots - Surgical robots saw a significant decline in December, with figures at 600 million yuan, down 24%, but are expected to reach 5.2 billion yuan in 2025, reflecting a robust growth of 54% [51]. Key Companies - Major companies in the sector include Mindray, which reported 1.9 billion yuan in December (+20%) and is projected to reach 11.2 billion yuan in 2025 (+35%), and United Imaging, with December figures of 2.2 billion yuan (0% change) and a forecast of 12.6 billion yuan (+37%) for 2025 [55][58].